✨ Free AI Report
Transgene SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Transgene SA
Research Preview

Transgene SA: Business Overview, Financials & Competitive Analysis

Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platf...

Analyst-debate audio for Transgene SA

AskCyborg analysts argue the bull and bear cases for Transgene SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Transgene SA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Transgene is a well-capitalized, clinical-stage immunotherapy leader with differentiated AI-driven personalized vaccine platform...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Oncology Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Transgene SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Transgene SA Overview

Pro stress-test →

Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platform represents a paradigm shift in precision medicine, generating individualized virus-based immunotherapies that encode patient-specific mutations identified through AI capabilities provided by partner NEC.

Strategic Profile

Pro stress-test →

TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is the company's lead asset with demonstrated proof of principle in patients for adjuvant treatment of head and neck cancers. The company has strategic collaborations with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation, positioning itself as a clinical-stage leader in individualized neoantigen therapeutic vaccines.

Competitive Landscape

Pro stress-test →

Transgene's portfolio includes TG4050 (individualized therapeutic vaccine), TG4001 (HPV vaccine), and BT-001 and TG6050 (oncolytic viruses). Key competitors in personalized neoantigen vaccines include BioNTech, CureVac, and other immunotherapy innovators. Transgene's differentiation lies in its clinically-validated myvac® platform and strong partnership ecosystem with major pharma players.

Industry Context

Transgene SA operates in Biopharmaceuticals - Oncology Immunotherapy.

Key facts

Founded: 1979 · Headquarters: Strasbourg, France · Employees: 160 · Market cap: $301M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Transgene SA.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Transgene SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

mRNA-based neoantigen vaccinesBioNTech personalized oncology program→Immunotherapy programsCancer immunotherapy portfolio (collaboration partner)→Therapeutic vaccinesmRNA-based therapeutic vaccines→

Compare Transgene SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Transgene SA operates in Biopharmaceuticals - Oncology Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Oncology Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Transgene SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Transgene SA and its top competitor on Cyborg Score”
“What did Transgene SA do this quarter?”
“Is Transgene SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Transgene SA do?+
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics. The company's proprietary myvac® platf...
What is Transgene SA's Cyborg Score?+
Transgene SA has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Transgene SA's main competitors?+
Named competitors include mRNA-based neoantigen vaccines, Immunotherapy programs, Therapeutic vaccines. The full competitive landscape is in the AskCyborg report.
How can I get the full Transgene SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Transgene SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Transgene SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.